261 related articles for article (PubMed ID: 9261752)
21. Ifosfamide nephrotoxicity in pediatric cancer patients.
Lee BS; Lee JH; Kang HG; Hahn H; Lee JH; Shin HY; Ha IS; Cheong HI; Ahn HS; Choi Y
Pediatr Nephrol; 2001 Oct; 16(10):796-9. PubMed ID: 11605785
[TBL] [Abstract][Full Text] [Related]
22. Nephrotoxicity of cis-diamminedichloroplatinum with or without ifosfamide in cancer treatment.
Hacke M; Schmoll HJ; Alt JM; Baumann K; Stolte H
Clin Physiol Biochem; 1983; 1(1):17-26. PubMed ID: 6383688
[TBL] [Abstract][Full Text] [Related]
23. The influence of age on nephrotoxicity following chemotherapy in children.
Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
Br J Cancer Suppl; 1992 Aug; 18():S30-5. PubMed ID: 1503924
[TBL] [Abstract][Full Text] [Related]
24. Nephrotoxicity after ifosfamide.
Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
Arch Dis Child; 1990 Jul; 65(7):732-8. PubMed ID: 2386379
[TBL] [Abstract][Full Text] [Related]
25. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.
Goren MP; Wright RK; Pratt CB; Horowitz ME; Dodge RK; Viar MJ; Kovnar EH
Cancer Res; 1987 Mar; 47(5):1457-60. PubMed ID: 3815347
[TBL] [Abstract][Full Text] [Related]
26. [Polymorphism at the glutathione S-transferase pi locus as a risk factor for ifosfamide nephrotoxicity in children].
Zielińska E; Zubowska M; Bodalski J
Pol Merkur Lekarski; 2003 Apr; 14(82):295-8. PubMed ID: 12868187
[TBL] [Abstract][Full Text] [Related]
27. Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation.
MacLean FR; Skinner R; Hall AG; English M; Pearson AD
Cancer Chemother Pharmacol; 1998; 41(5):413-6. PubMed ID: 9523738
[TBL] [Abstract][Full Text] [Related]
28. Tubulointerstitial nephritis following high-dose ifosfamide in three breast cancer patients.
Hill PA; Prince HM; Power DA
Pathology; 2000 Aug; 32(3):166-70. PubMed ID: 10968388
[TBL] [Abstract][Full Text] [Related]
29. Chronic ifosfamide nephrotoxicity in children.
Skinner R
Med Pediatr Oncol; 2003 Sep; 41(3):190-7. PubMed ID: 12868118
[TBL] [Abstract][Full Text] [Related]
30. [The kidney in children under chemotherapy].
Cachat F; Guignard JP
Rev Med Suisse Romande; 1996 Dec; 116(12):985-93. PubMed ID: 9026889
[TBL] [Abstract][Full Text] [Related]
31. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
[TBL] [Abstract][Full Text] [Related]
32. Ifosfamide nephrotoxicity in children: histopathological features in two cases.
Morland BJ; Mann JR; Milford DV; Raafat F; Stevens MC
Med Pediatr Oncol; 1996 Jul; 27(1):57-61. PubMed ID: 8614393
[TBL] [Abstract][Full Text] [Related]
33. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
[TBL] [Abstract][Full Text] [Related]
34. [Nephrotoxicity of ifosfamide with special reference to Fanconi Syndrome].
Rogowska E; Woźniak W
Med Wieku Rozwoj; 2004; 8(2 Pt 1):289-95. PubMed ID: 15738605
[TBL] [Abstract][Full Text] [Related]
35. [Renal tubular function in children with hypercalciuria].
Kovacević L; Kovacević S; Smoljanić Z; Kostić M; Peco-Antić A; Gajić M; Kovacević M; Jovanović O
Srp Arh Celok Lek; 1998; 126(7-8):223-7. PubMed ID: 9863386
[TBL] [Abstract][Full Text] [Related]
36. Renal function abnormalities after ifosfamide treatment in children.
De Schepper J; Hachimi-Idrissi S; Verboven M; Piepsz A; Otten J
Acta Paediatr; 1993 Apr; 82(4):373-6. PubMed ID: 8318805
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.
Suarez A; McDowell H; Niaudet P; Comoy E; Flamant F
J Clin Oncol; 1991 Dec; 9(12):2177-82. PubMed ID: 1720453
[TBL] [Abstract][Full Text] [Related]
38. Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
Ridola V; Fawaz O; Aubier F; Bergeron C; de Vathaire F; Pichon F; Orbach D; Gentet JC; Schmitt C; Dufour C; Oberlin O
Eur J Cancer; 2009 Mar; 45(5):814-8. PubMed ID: 19216070
[TBL] [Abstract][Full Text] [Related]
39. [High-dose ifosfamide in the treatment of patients with soft tissue sarcoma].
Tiuliandin SA; Liubimova NV; Sidorova NI; Averinova SG; Kashkadaeva AV; Romanova LF; Shiriaev SV; Garin AM
Vopr Onkol; 1996; 42(6):19-22. PubMed ID: 9123896
[TBL] [Abstract][Full Text] [Related]
40. The utility of (99m)Tc-DMSA and Tc(99m)-EC scintigraphy for early diagnosis of ifosfamide induced nephrotoxicity.
Caglar M; Yarís N; Akyuz C
Nucl Med Commun; 2001 Dec; 22(12):1325-32. PubMed ID: 11711903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
